ArticleCardiovascular intervention and therapeutics2026
Comparative analysis of biologic drug effects and distal particulate embolization among three drug-coated balloons: a histological and biological study in a rabbit model.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Periprocedural echocardiographic guidance for transcatheter paravalvular leak closure: from patient selection to follow-up.Journal of echocardiography · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-coated balloons (DCBs) have improved clinical outcomes in femoropopliteal interventions; however, distal particulate embolization remains a critical concern, particularly in patients with chronic limb-threatening ischemia. This study aimed to histologically and biologically compare local drug effects and distal embolization among three contemporary DCBs: Ranger, IN.PACT Admiral, and Luminor. Eighteen healthy rabbits underwent descending aorta balloon angioplasty followed by DCB inflation. Animals were divided into three groups (n = 6 each): Ranger (2.0 µg/mm², 3-minute inflation), IN.PACT (3.5 µg/mm², 3-minute inflation), and Luminor (3.0 µg/mm², 1-minute inflation). At 28 days, treated aortas and downstream skeletal muscles were evaluated histopathologically and for tissue paclitaxel concentrations. In the target lesions, median paclitaxel concentrations were comparable among the Ranger, IN.PACT, and Luminor groups (3047.5, 1537.1, and 551.5 fmol/mg, respectively). Consistent with this, histological evaluations demonstrated robust and comparable medial smooth muscle cell loss across all devices. Conversely, evaluation of downstream skeletal muscles revealed striking differences in distal drug washout. Distal muscle paclitaxel concentrations were significantly higher in the Luminor group (1069.4 fmol/mg) compared to the IN.PACT (354.8 fmol/mg) and Ranger (173.8 fmol/mg) groups. Histologically, the incidence of distal particulate embolization was most severe in the Luminor group (median 4.0), followed by the IN.PACT group (3.0), both higher than the Ranger group (1.0). The low-dose Ranger DCB achieved robust drug delivery with significantly lower distal embolization risk than high-dose DCBs. These mechanistic insights may guide device selection, but clinical studies are needed to confirm limb outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.